See more : Zhejiang Tieliu Clutch Co., Ltd. (603926.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Sutro Biopharma, Inc. (STRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sutro Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Danske Invest – Global Sustainable Future Akk (DKIGSFUT.CO) Income Statement Analysis – Financial Results
- The Joint Corp. (JYNT) Income Statement Analysis – Financial Results
- Peninsula Group Ltd (PEN.TA) Income Statement Analysis – Financial Results
- Compass Group PLC (CMPGF) Income Statement Analysis – Financial Results
- Midnight Sun Mining Corp. (MDNGF) Income Statement Analysis – Financial Results
Sutro Biopharma, Inc. (STRO)
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 153.73M | 67.77M | 61.88M | 42.72M | 42.74M | 38.42M | 51.74M | 59.73M |
Cost of Revenue | 6.82M | 8.29M | 9.77M | 76.96M | 65.61M | 54.26M | 51.90M | 43.55M |
Gross Profit | 146.92M | 59.48M | 52.11M | -34.24M | -22.88M | -15.84M | -156.00K | 16.18M |
Gross Profit Ratio | 95.57% | 87.77% | 84.21% | -80.14% | -53.53% | -41.24% | -0.30% | 27.09% |
Research & Development | 180.43M | 137.17M | 104.40M | 76.96M | 65.61M | 54.26M | 54.64M | 43.55M |
General & Administrative | 62.58M | 59.54M | 56.00M | 36.82M | 32.59M | 21.38M | 16.37M | 14.82M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 62.58M | 59.54M | 56.00M | 36.82M | 32.59M | 21.38M | 16.37M | 14.82M |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -4.35M | 1.91M | -77.00K | 87.00K |
Operating Expenses | 243.01M | 196.72M | 160.40M | 113.78M | 98.20M | 75.64M | 71.01M | 58.37M |
Cost & Expenses | 243.01M | 196.72M | 160.40M | 113.78M | 98.20M | 75.64M | 71.01M | 58.37M |
Interest Income | 14.51M | 3.46M | 577.00K | 1.51M | 4.07M | 1.62M | 273.00K | 251.00K |
Interest Expense | 23.75M | 3.35M | 3.14M | 4.08M | 4.35M | 1.62M | 612.00K | 0.00 |
Depreciation & Amortization | 6.82M | 8.29M | 9.77M | 4.30M | 4.78M | 4.54M | 4.99M | 5.66M |
EBITDA | -67.92M | -105.07M | -98.52M | -23.75M | -46.62M | -32.82M | -14.09M | 7.36M |
EBITDA Ratio | -44.18% | -185.16% | -150.46% | -152.74% | -109.08% | -75.89% | -27.22% | 12.33% |
Operating Income | -89.28M | -128.94M | -98.52M | -71.06M | -55.47M | -37.22M | -19.27M | 1.36M |
Operating Income Ratio | -58.07% | -190.26% | -159.22% | -166.32% | -129.79% | -96.89% | -37.25% | 2.28% |
Total Other Income/Expenses | 677.00K | 12.24M | -7.01M | 38.93M | -276.00K | 1.91M | -416.00K | 338.00K |
Income Before Tax | -88.60M | -116.70M | -105.54M | -32.13M | -55.74M | -35.32M | -19.69M | 1.70M |
Income Before Tax Ratio | -57.63% | -172.20% | -170.55% | -75.20% | -130.44% | -91.93% | -38.05% | 2.85% |
Income Tax Expense | 18.19M | 2.50M | 3.14M | 4.08M | 8.68M | 3.53M | 535.00K | 87.00K |
Net Income | -106.79M | -119.20M | -108.68M | -36.21M | -55.74M | -35.32M | -19.69M | 1.70M |
Net Income Ratio | -69.47% | -175.89% | -175.62% | -84.75% | -130.44% | -91.93% | -38.05% | 2.85% |
EPS | -1.78 | -2.35 | -2.36 | -1.11 | -2.43 | -6.13 | -2.81 | 0.24 |
EPS Diluted | -1.78 | -2.35 | -2.36 | -1.11 | -2.43 | -6.13 | -2.81 | 0.24 |
Weighted Avg Shares Out | 60.16M | 50.74M | 46.12M | 32.57M | 22.96M | 5.76M | 7.00M | 7.00M |
Weighted Avg Shares Out (Dil) | 60.16M | 50.74M | 46.12M | 32.57M | 22.96M | 5.76M | 7.00M | 7.00M |
Sutro Biopharma to Participate in Upcoming Investor Conferences
World’s First AutoStore Solution With Frozen Food Zone to Be Installed by StrongPoint
La première solution AutoStore au monde avec zone d’aliments surgelés sera installée par StrongPoint
StrongPoint installiert weltweit erste AutoStore-Lösung mit Tiefkühlbereich
‘s Werelds eerste AutoStore-oplossing met Frozen Food Zone die wordt geïnstalleerd door StrongPoint
StrongPoint instalará la primera solución de AutoStore del mundo con zona de congelados
La prima soluzione AutoStore al mondo con Zona Surgelati sarà installata da StrongPoint
StrongPoint uzstādīs pasaulē pirmo AutoStore risinājumu ar saldētu pārtikas produktu pārvaldību
StrongPoint diegs pirmąjį pasaulyje AutoStore sprendimą su zona šaldytiems maisto produktams
Ettevõtte AutoStore maailma esimese külmutatud toidukaubale mõeldud lahenduse paigaldab StrongPoint
Source: https://incomestatements.info
Category: Stock Reports